Johnson & Johnson Fiscal Q2 Adjusted Earnings, Sales Increase; Fiscal 2026 Guidance Lifted
Johnson & Johnson (JNJ) reported fiscal Q2 adjusted earnings Wednesday of $2.90 per diluted share, up from $2.77 a year earlier. Analysts polled by FactSet expected $2.85. Reported sales for the fiscal quarter ended June 28 were $25.31 billion, up from $23.74 billion a year earlier. Analysts surveyed by FactSet expected $25.02 billion. For fiscal 2026, the pharmaceuticals major lifted its projected adjusted EPS guidance to between $11.60 and $11.75 from a previous range of $11.45 to $11.65 and its reported sales to between $100.8 billion to $101.4 billion from a previous range of $100.3 billion to $101.3 billion. Analysts polled by FactSet expect $11.59 and $101.06 billion. Shares of the company were down 1% in recent Wednesday premarket activity.
Johnson & Johnson (JNJ) reported fiscal Q2 adjusted earnings Wednesday of $2.90 per diluted share, up from $2.77 a year earlier.
Analysts polled by FactSet expected $2.85.
Reported sales for the fiscal quarter ended June 28 were $25.31 billion, up from $23.74 billion a year earlier.
Analysts surveyed by FactSet expected $25.02 billion.
For fiscal 2026, the pharmaceuticals major lifted its projected adjusted EPS guidance to between $11.60 and $11.75 from a previous range of $11.45 to $11.65 and its reported sales to between $100.8 billion to $101.4 billion from a previous range of $100.3 billion to $101.3 billion.
Analysts polled by FactSet expect $11.59 and $101.06 billion.
Shares of the company were down 1% in recent Wednesday premarket activity.